{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:42:11Z","timestamp":1789756931624,"version":"4.0.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The injection of transurethral bulking agents is an office procedure that has been used as a primary and secondary treatment to improve urethral coaptation and restore urinary continence. The treatment has been available in the US since January 2020. In this study, we aim to present our experience with the efficacy of Bulkamid transurethral injection as a primary and secondary treatment among women with stress urinary incontinence (SUI) or mixed urinary incontinence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This is a retrospective study that was performed on 100 patients who received Bulkamid as primary or secondary treatment. The data were collected by reviewing medical records. The procedure was performed in the office with the injection of local anesthesia. The patients were followed up approximately 30 days after the procedure and the efficacy of Bulkamid injection was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      One hundred patients were evaluated upon returning to the office. The mean age of patients was 62 years, and the mean body mass index was 29. Forty-eight patients have received Bulkamid treatment for stress incontinence as a primary procedure and 49 as a salvage procedure. The mean satisfaction reported by the patients was 53.7% for the primary group and 69.69% for the secondary group, with a\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0187 which is statistically different. There are no complications reported in the follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Bulkamid transurethral injection appears to be a safe and effective treatment option for women with primary and secondary SUI. There is a trend toward higher short-term satisfaction in patients with previous anti-incontinence procedures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/gmit.gmit-d-24-00027","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T15:00:20Z","timestamp":1752937220000},"page":"241-245","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The Efficacy of Polyacrylamide Hydrogel (Bulkamid) Transurethral Injection System: The Outcome of Short-term Follow-up of 100 Cases"],"prefix":"10.4103","volume":"14","author":[{"given":"Ekhlas","family":"Abdulraheem","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaleida Health, Affiliated with Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdorrahman","family":"Attuwaybi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaleida Health, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaleida Health, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Eddib","sequence":"additional","affiliation":[{"name":"Department of Urogynecology, Kaleida Health, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/GMIT.GMIT_72_18","article-title":"Interventions and quality of life in stress urinary incontinence","volume":"8","author":"Pandey","year":"2019","journal-title":"Gynecol Minim Invasive Ther"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/SPV.0000000000001127","article-title":"Updated prevalence of urinary incontinence in women: 2015-2018 national population-based survey data","volume":"28","author":"Patel","year":"2022","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/01.AOG.0000206213.48334.09","article-title":"The \u201ccosts\u201d of urinary incontinence for women","volume":"107","author":"Subak","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R5-20250804","first-page":"CD006375","article-title":"Mid-urethral sling operations for stress urinary incontinence in women","volume":"7","author":"Ford","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/GMIT.GMIT_7_19","article-title":"Current treatments for female pelvic floor dysfunctions","volume":"8","author":"Hong","year":"2019","journal-title":"Gynecol Minim Invasive Ther"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/GCO.0000000000000579","article-title":"Old wine into new wineskins: An update for female stress urinary incontinence","volume":"31","author":"Shaw","year":"2019","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/JU.0000000000000517","article-title":"Tension-free vaginal tape surgery versus polyacrylamide hydrogel injection for primary stress urinary incontinence: A randomized clinical trial","volume":"203","author":"Itkonen","year":"2020","journal-title":"J Urol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00192-008-0741-5","article-title":"Effects of macroplastique implantation system for stress urinary incontinence and urethral hypermobility in women","volume":"20","author":"ter Meulen","year":"2009","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1464-410X.2006.06205.x","article-title":"A new bulking agent (polyacrylamide hydrogel) for treating stress urinary incontinence in women","volume":"98","author":"Lose","year":"2006","journal-title":"BJU Int"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/nau.24589","article-title":"Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence","volume":"40","author":"Brosche","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"25","DOI":"10.12788\/obgm.0043","article-title":"Urethral bulking agents for SUI: Rethinking their indications","volume":"32","author":"Hoover","year":"2020","journal-title":"OBG Manage"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00192-010-1214-1","article-title":"An open multicenter study of polyacrylamide hydrogel (Bulkamid\u00ae) for female stress and mixed urinary incontinence","volume":"21","author":"Lose","year":"2010","journal-title":"Int Urogynecol J"},{"key":"R14-20250804","first-page":"428","article-title":"Durability, safety and efficacy of polyacrylamide hydrogel (Bulkamid(\u00ae)) in the management of stress and mixed urinary incontinence: Three year follow up outcomes","volume":"68","author":"Pai","year":"2015","journal-title":"Cent European J Urol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/aogs.12283","article-title":"Long-term follow-up after urethral injection with polyacrylamide hydrogel for female stress incontinence","volume":"93","author":"Mouritsen","year":"2014","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/jcm11061569","article-title":"Urethral bulking in the treatment of stress and mixed female urinary incontinence: Results from a multicenter cohort and predictors of clinical outcomes","volume":"11","author":"Giamm\u00f2","year":"2022","journal-title":"J Clin Med"}],"container-title":["Gynecology and Minimally Invasive Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/gmit.GMIT-D-24-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:27:19Z","timestamp":1786724839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/gmit.GMIT-D-24-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/gmit.gmit-d-24-00027","relation":{},"ISSN":["2213-3070","2213-3089"],"issn-type":[{"value":"2213-3070","type":"print"},{"value":"2213-3089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-09-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}